

# Vasilios G. Athyros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2817635/publications.pdf>

Version: 2024-02-01

383  
papers

12,815  
citations

24978

57  
h-index

32761

100  
g-index

387  
all docs

387  
docs citations

387  
times ranked

12428  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet</i> , The, 2010, 376, 1916-1922.	6.3	594
2	The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2692-2701.	1.8	518
3	Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention. <i>Current Medical Research and Opinion</i> , 2002, 18, 220-228.	0.9	510
4	The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. <i>Journal of Clinical Pathology</i> , 2004, 57, 728-734.	1.0	316
5	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017, 75, 307-326.	2.6	294
6	Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia. <i>Diabetes Care</i> , 2002, 25, 1198-1202.	4.3	253
7	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006, 22, 873-883.	0.9	238
8	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1293-1301.	1.5	236
9	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 589-599.	2.1	224
10	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	1.5	208
11	Diabetes and lipid metabolism. <i>Hormones</i> , 2018, 17, 61-67.	0.9	192
12	&#x201C;European Panel on Low Density Lipoprotein (LDL) Subclasses&#x201D;: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. <i>Current Vascular Pharmacology</i> , 2011, 9, 533-571.	0.8	187
13	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. <i>Review of Diabetic Studies</i> , 2015, 12, 110-118.	0.5	169
14	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , 2005, 21, 1157-1159.	0.9	165
15	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> . 2006. 22. 118-127.	0.4	158
16	Long-term Follow-up of Patients With Acute Hypertriglyceridemia-Induced Pancreatitis. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 472-475.	1.1	156
17	Safety and Efficacy of Long-Term Statin-Fibrate Combinations in Patients With Refractory Familial Combined Hyperlipidemia. <i>American Journal of Cardiology</i> , 1997, 80, 608-613.	0.7	149
18	Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. <i>Osteoporosis International</i> , 2009, 20, 197-207.	1.3	146

#	ARTICLE	IF	CITATIONS
19	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
20	Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 140-146.	1.1	139
21	The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre Study. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 397-405.	2.2	134
22	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. <i>Angiology</i> , 2007, 58, 689-697.	0.8	133
23	Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. <i>American Heart Journal</i> , 2004, 148, 635-640.	1.2	130
24	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 7860.	1.4	130
25	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
26	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 302-312.	2.2	123
27	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
28	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. <i>Circulation Journal</i> , 2007, 71, 1120-1127.	0.7	119
29	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 509-515.	0.9	115
30	Pheochromocytoma: an update on genetics and management. <i>Endocrine-Related Cancer</i> , 2007, 14, 935-956.	1.6	114
31	&#x201C;European Panel On Low Density Lipoprotein (LDL) Subclasses&#x201D;: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. <i>Current Vascular Pharmacology</i> , 2011, 9, 531-532.	0.8	110
32	Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?. <i>Current Drug Targets</i> , 2010, 11, 122-135.	1.0	100
33	Contrast-Induced Nephropathy. <i>Angiology</i> , 2015, 66, 508-513.	0.8	96
34	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010, 26, 713-719.	0.9	93
35	Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. <i>Atherosclerosis</i> , 2001, 157, 463-469.	0.4	92
36	Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus. <i>Angiology</i> , 2003, 54, 679-690.	0.8	91

#	ARTICLE	IF	CITATIONS
37	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. <i>Atherosclerosis</i> , 2007, 193, 428-437.	0.4	88
38	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 21-33.	1.5	87
39	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1691-1701.	0.9	84
40	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , 2008, 200, 1-12.	0.4	79
41	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. <i>Journal of Human Hypertension</i> , 2004, 18, 781-788.	1.0	78
42	Prevalence of vascular disease in metabolic syndrome using three proposed definitions. <i>International Journal of Cardiology</i> , 2007, 117, 204-210.	0.8	78
43	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 74-82.	2.3	75
44	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.4	72
45	Cardiovascular benefits of bariatric surgery in morbidly obese patients. <i>Obesity Reviews</i> , 2011, 12, 515-524.	3.1	72
46	Effect of atorvastatin on highdensity lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREEK Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 627-637.	0.9	69
47	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	1.0	69
48	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2018, 16, 246-253.	0.8	69
49	Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	0.9	68
50	Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. <i>American Journal of Cardiology</i> , 2008, 101, 483-485.	0.7	68
51	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009, 8, 163-184.	0.9	68
52	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1215-1223.	1.5	68
53	Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. <i>Current Medical Research and Opinion</i> , 2003, 19, 22-27.	0.9	67
54	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2003, 19, 615-617.	0.9	67

#	ARTICLE	IF	CITATIONS
55	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	1.5	66
56	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 213-221.	1.1	66
57	Hyperuricaemia. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 397-402.	0.6	66
58	The ORlistat and Cardiovascular risk profile in patients with metabolic syndrome and type 2 Diabetes (ORliCARDIA) study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1393-1401.	0.9	61
59	Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. <i>Coronary Artery Disease</i> , 1996, 7, 843-850.	0.3	59
60	Uric acid levels and vascular disease. <i>Current Medical Research and Opinion</i> , 2004, 20, 951-954.	0.9	57
61	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 24-34.	0.6	55
62	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , 2020, 18, 172-181.	0.8	54
63	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018, 16, 130-142.	0.8	54
64	Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2010, 8, 720-730.	0.8	53
65	Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2011, 9, 698-705.	0.8	53
66	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	0.8	52
67	Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. <i>American Journal of Cardiology</i> , 1996, 77, 242-246.	0.7	50
68	Role of Antihypertensive Drugs in Arterial $\hat{\epsilon}$ -De-Stiffening $\hat{\epsilon}$ <sup>TM</sup> and Central Pulsatile Hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 143-156.	1.0	49
69	Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview. <i>Current Vascular Pharmacology</i> , 2014, 12, 627-641.	0.8	48
70	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011, 27, 1659-1668.	0.9	47
71	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014, 29, 389-395.	0.8	47
72	Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review. <i>International Journal of Nanomedicine</i> , 2006, 1, 129-147.	3.3	46

#	ARTICLE	IF	CITATIONS
73	Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures. <i>Current Drug Targets</i> , 2007, 8, 942-951.	1.0	46
74	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary heart disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.4	46
75	Left Ventricular Systolic and Diastolic Function in Normotensive Type 1 Diabetic Patients With or Without Autonomic Neuropathy: A radionuclide ventriculography study. <i>Diabetes Care</i> , 2003, 26, 1955-1960.	4.3	45
76	Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2006, 4, 175-183.	0.8	44
77	Statin discontinuation: an underestimated risk?. <i>Current Medical Research and Opinion</i> , 2008, 24, 3059-3062.	0.9	44
78	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. <i>Current Vascular Pharmacology</i> , 2011, 9, 647-657.	0.8	44
79	Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 1-7.	1.2	43
80	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1449-1461.	0.9	43
81	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. <i>Current Vascular Pharmacology</i> , 2012, 10, 162-172.	0.8	42
82	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2019, 24, 4587-4592.	0.9	42
83	Definitions of Metabolic Syndrome: Where are We Now?. <i>Current Vascular Pharmacology</i> , 2006, 4, 185-197.	0.8	40
84	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.4	40
85	Ezetimibe Therapy for Dyslipidemia: An Update. <i>Current Pharmaceutical Design</i> , 2013, 19, 3107-3114.	0.9	40
86	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1143-1160.	1.5	39
87	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <i>Annals of Medicine</i> , 2011, 43, 167-171.	1.5	39
88	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	1.0	38
89	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	0.9	38
90	Statins and Solid Organ Transplantation. <i>Current Pharmaceutical Design</i> , 2006, 12, 4771-4783.	0.9	37

#	ARTICLE	IF	CITATIONS
91	The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 642-652.	1.0	37
92	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. <i>International Journal of Clinical Practice</i> , 2011, 65, 679-683.	0.8	37
93	Total Serum Insulin-like Growth Factor-1 and C-Reactive Protein in Metabolic Syndrome With or Without Diabetes. <i>Angiology</i> , 2006, 57, 303-311.	0.8	36
94	Atherogenesis in Renal Patients: A Model of Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2008, 6, 93-107.	0.8	36
95	Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. <i>Lipids</i> , 2007, 42, 999-1009.	0.7	35
96	Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report. <i>Current Vascular Pharmacology</i> , 2014, 12, 505-511.	0.8	35
97	Fish Oils and Vascular Disease Prevention: An Update. <i>Current Medicinal Chemistry</i> , 2007, 14, 2622-2628.	1.2	34
98	Dysmetabolic Iron Overload in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2020, 26, 1019-1024.	0.9	34
99	Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 521-522.	1.2	33
100	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , 2004, 66, 1714-1715.	2.6	32
101	High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?. <i>Current Medicinal Chemistry</i> , 2014, 21, 2917-2926.	1.2	32
102	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 33-39.	1.5	30
103	Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. <i>International Journal of Clinical Practice</i> , 2007, 61, 545-551.	0.8	30
104	Is There an Association Between Inflammatory Bowel Diseases and Carotid Intima-media Thickness? Preliminary Data. <i>Angiology</i> , 2014, 65, 543-550.	0.8	30
105	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. <i>Platelets</i> , 2005, 16, 65-71.	1.1	29
106	The natural history of recently diagnosed autonomic neuropathy over a period of 2 years. <i>Diabetes Research and Clinical Practice</i> , 1998, 42, 55-63.	1.1	27
107	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
108	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	1.0	27

#	ARTICLE	IF	CITATIONS
109	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010, 25, 394-398.	0.8	27
110	Statins and new-onset diabetes mellitusâ€”a matter for debate. <i>Nature Reviews Endocrinology</i> , 2012, 8, 133-134.	4.3	27
111	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. <i>Angiology</i> , 2012, 63, 358-366.	0.8	27
112	New statin guidelines and promising novel therapeutics. <i>Nature Reviews Cardiology</i> , 2014, 11, 72-74.	6.1	27
113	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , 2007, 1, 8-14.	0.6	27
114	Anti-Inflammatory Effects of Fibrates: An Overview. <i>Current Medicinal Chemistry</i> , 2009, 16, 676-684.	1.2	26
115	Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. <i>International Journal of Cardiology</i> , 2009, 134, 322-329.	0.8	26
116	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010, 32, 326-331.	0.6	26
117	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , 2018, 277, 308-313.	0.4	26
118	Statins for non-alcoholic fatty liver disease: a new indication?. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 698-699.	1.9	25
119	Carotid Intima-Media Thickness in Patients With Inflammatory Bowel Disease. <i>Angiology</i> , 2014, 65, 284-293.	0.8	25
120	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 191-205.	1.5	24
121	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 693-700.	1.6	24
122	Short-term statin therapy for prevention of contrast-induced AKI. <i>Nature Reviews Nephrology</i> , 2014, 10, 8-9.	4.1	24
123	Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 84, 1164-1169.	0.7	23
124	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	0.8	23
125	Thinking Beyond Traditional Cardiovascular Risk Factors. <i>Angiology</i> , 2012, 63, 9-11.	0.8	23
126	Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?). <i>Current Vascular Pharmacology</i> , 2012, 10, 374-377.	0.8	23



#	ARTICLE	IF	CITATIONS
127	Are statins "IDEAL"™ for non-alcoholic fatty liver disease?. <i>Current Medical Research and Opinion</i> , 2014, 30, 229-231.	0.9	23
128	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. <i>Maturitas</i> , 2018, 108, 45-52.	1.0	23
129	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. <i>Endocrine</i> , 2020, 69, 249-261.	1.1	23
130	Statin-fibrate combinations in patients with combined hyperlipidemia. <i>Atherosclerosis</i> , 2001, 155, 263-264.	0.4	22
131	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1593-1599.	0.9	22
132	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 723-730.	0.9	22
133	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010, 26, 839-842.	0.9	22
134	Atorvastatin versus Four Statin-Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 33-39.	3.1	21
135	Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2002, 163, 205-206.	0.4	21
136	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	0.9	21
137	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia. <i>Clinical Drug Investigation</i> , 1998, 16, 219-227.	1.1	20
138	Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. <i>Current Medical Research and Opinion</i> , 2009, 25, 971-980.	0.9	20
139	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 936-944.	0.6	20
140	Hyperuricemia as a risk factor for cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 19-20.	0.6	19
141	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 43-46.	1.5	19
142	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 19-26.	1.7	19
143	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , 2018, 12, 29-40.	0.6	19
144	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. <i>Angiology</i> , 2022, 73, 87-87.	0.8	19

#	ARTICLE	IF	CITATIONS
145	Statins for the Prevention of First or Recurrent Stroke. <i>Current Vascular Pharmacology</i> , 2008, 6, 124-133.	0.8	19
146	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	0.8	19
147	Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?. <i>Current Vascular Pharmacology</i> , 2018, 16, 269-275.	0.8	19
148	Statins and renal function. Is the compound and dose making a difference?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 963-964.	0.4	18
149	Vitamin D deficiency, statin-related myopathy and other links with vascular risk. <i>Current Medical Research and Opinion</i> , 2011, 27, 1691-1692.	0.9	18
150	Lipid Lowering Agents and the Endothelium: An Update after 4 Years. <i>Current Vascular Pharmacology</i> , 2012, 10, 33-41.	0.8	18
151	Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment. <i>Current Vascular Pharmacology</i> , 2015, 13, 788-800.	0.8	18
152	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 55-60.	0.6	18
153	Metabolic syndrome and arterial stiffness. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 687-689.	0.6	17
154	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 331-339.	1.4	17
155	Colesevelam: A New and Improved Bile Acid Sequestrant?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3115-3123.	0.9	17
156	Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity. <i>Current Vascular Pharmacology</i> , 2010, 8, 646-660.	0.8	17
157	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. <i>Hellenic Journal of Cardiology</i> , 2005, 46, 380-6.	0.4	17
158	Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 499-502.	0.9	16
159	Intravenous Immunoglobulins: A Valuable Asset in the Treatment of a Case of Septic Febrile Ulceronecrotic Mucha-Habermann Disease. <i>Dermatology</i> , 2007, 215, 164-165.	0.9	16
160	High Density Lipoprotein Cholesterol and Statin Trials. <i>Current Medicinal Chemistry</i> , 2008, 15, 2265-2270.	1.2	16
161	Lipid-lowering agents and new onset diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1965-1970.	0.9	16
162	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. <i>Current Vascular Pharmacology</i> , 2021, 19, 572-581.	0.8	16

#	ARTICLE	IF	CITATIONS
163	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. <i>Current Pharmaceutical Design</i> , 2018, 24, 1879-1886.	0.9	16
164	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 26-34.	0.6	16
165	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1385-1392.	0.9	15
166	Omega-3 fatty acids: How can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 510-517.	2.0	15
167	Myocardial perfusion scintigraphy in asymptomatic diabetic patients: a critical review. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 336-347.	1.7	15
168	Brain natriuretic peptide and the athlete's heart: a pilot study. <i>International Journal of Clinical Practice</i> , 2010, 64, 511-517.	0.8	15
169	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 142-145.	1.2	15
170	Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. <i>Current Vascular Pharmacology</i> , 2016, 14, 494-497.	0.8	15
171	Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 293-293.	0.4	14
172	The Effect of Cholesterol-Lowering Treatment on Renal Function. <i>American Journal of Kidney Diseases</i> , 2006, 47, 561.	2.1	14
173	Statin Treatment May be Beneficial to Both the Kidneys and the Heart. <i>Peritoneal Dialysis International</i> , 2007, 27, 215-216.	1.1	14
174	Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome. <i>Angiology</i> , 2010, 61, 49-57.	0.8	14
175	Stage of chronic kidney disease and severity of coronary heart disease manifestation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 457-460.	0.9	14
176	Should raising high-density lipoprotein cholesterol be a matter of debate?. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 254-259.	0.6	14
177	Nonalcoholic Fatty Liver Disease and Severity of Cardiovascular Disease Manifestations. <i>Angiology</i> , 2013, 64, 572-575.	0.8	14
178	Uric acid, chronic kidney disease and type 2 diabetes: A cluster of vascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 122-123.	1.2	14
179	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <i>Current Medical Research and Opinion</i> , 2016, 32, 1513-1514.	0.9	14
180	Semaglutide, lipid-lowering drugs, and NAFLD. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 329-330.	5.5	14

#	ARTICLE	IF	CITATIONS
181	Management of Statin-Intolerant High-Risk Patients. <i>Current Vascular Pharmacology</i> , 2010, 8, 632-637.	0.8	14
182	Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Drug Investigation</i> , 1994, 7, 134-142.	0.6	13
183	Effect of Aldose Reductase Inhibition on Cardiovascular Reflex Tests in Patients with Definite Diabetic Autonomic Neuropathy Over a Period of 2 Years. <i>Journal of Diabetes and Its Complications</i> , 1998, 12, 201-207.	1.2	13
184	Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 145-147.	1.0	13
185	Effect of Apolipoprotein E Polymorphism on Serum Uric Acid Levels in Healthy Subjects. <i>Journal of Investigative Medicine</i> , 2005, 53, 116-122.	0.7	13
186	Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 969-972.	1.9	13
187	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. <i>Current Vascular Pharmacology</i> , 2010, 8, 792-803.	0.8	13
188	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 362-363.	5.5	13
189	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2018, 16, 214-218.	0.8	13
190	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. <i>Current Vascular Pharmacology</i> , 2018, 16, 254-268.	0.8	13
191	Effect of Aldose Reductase Inhibition on Heart Rate Variability in Patients with Severe or Moderate Diabetic Autonomic Neuropathy. <i>Clinical Drug Investigation</i> , 1998, 15, 111-121.	1.1	12
192	Inflammatory markers and the metabolic syndrome. <i>Atherosclerosis</i> , 2005, 183, 187-188.	0.4	12
193	Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 197-198.	0.2	12
194	A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. <i>Current Medical Research and Opinion</i> , 2007, 23, 1945-1956.	0.9	12
195	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 809-820.	1.5	12
196	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 16-17.	2.9	12
197	Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]. <i>Current Vascular Pharmacology</i> , 2009, 7, 264-266.	0.8	12
198	Blood Pressure Levels Constitute the Most Important Determinant of the Metabolic Syndrome in a Mediterranean Population: A Discrimination Analysis. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 523-529.	0.5	12

#	ARTICLE	IF	CITATIONS
199	Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. <i>Current Vascular Pharmacology</i> , 2016, 14, 523-533.	0.8	12
200	DRY COUGH AS FIRST MANIFESTATION OF GIANT-CELL ARTERITIS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1957-1958.	1.3	11
201	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	0.9	11
202	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. <i>Current Pharmaceutical Design</i> , 2007, 13, 229-239.	0.9	11
203	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1931-1940.	0.9	11
204	Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3839-3847.	0.9	11
205	Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 85-89.	0.6	11
206	Statins and nonalcoholic fatty liver disease: a bright future?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1089-1093.	1.9	11
207	Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. <i>Current Vascular Pharmacology</i> , 2015, 13, 368-380.	0.8	11
208	Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. <i>Angiology</i> , 2009, 60, 74-81.	0.8	10
209	Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2015, 31, 191-195.	0.9	10
210	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 241-242.	1.8	10
211	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 942-948.	1.0	10
212	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , 2019, 24, 3638-3646.	0.9	10
213	Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 575-580.	0.6	10
214	Effects of various fibrates on serum alkaline phosphatase activity. <i>Atherosclerosis</i> , 2002, 165, 187-188.	0.4	9
215	Statins and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1644-1645.	1.2	9
216	Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?. <i>Angiology</i> , 2011, 62, 285-290.	0.8	9

#	ARTICLE	IF	CITATIONS
217	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Archives of Medical Science, 2011, 6, 1067-1075.	0.4	9
218	Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences, 2012, 57, 1109-1109.	1.1	9
219	Beliefs and attitudes regarding cardiovascular disease risk factors: A health survey in 10,141 Greek men and women (2006-2012). International Journal of Cardiology, 2013, 168, 4847-4849.	0.8	9
220	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment, 2013, 2, 67-71.	1.1	9
221	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Current Medical Research and Opinion, 2014, 30, 1701-1705.	0.9	9
222	Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?. Current Vascular Pharmacology, 2016, 14, 313-315.	0.8	9
223	Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in) Tj ETQq1 1 0.784314 rgBj /Overlock Pharmacology, 2016, 14, 469-473.	0.8	9
224	Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2206-2212.	0.9	9
225	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9
226	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Hormones, 2017, 16, 306-312.	0.9	9
227	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
228	Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure. Current Pharmaceutical Design, 2014, 20, 6306-6313.	0.9	9
229	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. Current Vascular Pharmacology, 2018, 16, 393-400.	0.8	9
230	Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. Atherosclerosis, 2003, 168, 397-398.	0.4	8
231	Undertreatment of dyslipidaemia in Greece. Atherosclerosis, 2004, 177, 215-216.	0.4	8
232	Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 913-915.	0.2	8
233	Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opinion on Investigational Drugs, 2008, 17, 445-449.	1.9	8
234	JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion, 2009, 25, 133-137.	0.9	8

#	ARTICLE	IF	CITATIONS
235	Relation of Improvement in Glomerular Filtration Rate With Atorvastatin to Reductions in Heart Failure Morbidity. <i>American Journal of Cardiology</i> , 2012, 110, 763.	0.7	8
236	Statins in Patients With Renal Dysfunction. <i>American Journal of Cardiology</i> , 2012, 109, 1537.	0.7	8
237	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 361.	5.5	8
238	Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2015, 14, 88-97.	0.8	8
239	High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 9-11.	1.2	8
240	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 241-251.	1.0	8
241	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. <i>Hormones</i> , 2022, 21, 91-101.	0.9	8
242	Statins and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2197.	3.8	7
243	CORONA, Statins, and Heart Failure: Who Lost the Crown?. <i>Angiology</i> , 2008, 59, 5-8.	0.8	7
244	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	0.9	7
245	To switch (statins) or not to switch? That is the question. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2943-2946.	0.9	7
246	Editorial: Statin Potency, LDL Receptors and New Onset Diabetes. <i>Current Vascular Pharmacology</i> , 2014, 12, 739-740.	0.8	7
247	Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2015, 13, 366-367.	0.8	7
248	Antihypertensive therapy in acute ischemic stroke: where do we stand?. <i>Journal of Human Hypertension</i> , 2018, 32, 799-807.	1.0	7
249	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , 2019, 17, 425-428.	0.8	7
250	Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1437-1440.	0.9	6
251	Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]. <i>Current Vascular Pharmacology</i> , 2008, 6, 81-83.	0.8	6
252	Smoking and non-alcoholic steatohepatitis (NASH): The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. <i>Journal of Hepatology</i> , 2012, 57, 476.	1.8	6

#	ARTICLE	IF	CITATIONS
253	Is There Any Association Between Adiponectin Gene Polymorphisms and Cardiovascular Disease?. <i>Angiology</i> , 2013, 64, 253-256.	0.8	6
254	More news from IMPROVE-IT (IMPROved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Hormones</i> , 2016, 15, 5-7.	0.9	6
255	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e1-e2.	1.5	6
256	Pharmacological Management of Type 2 Diabetes Complications. <i>Current Vascular Pharmacology</i> , 2020, 18, 101-103.	0.8	6
257	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , 2017, 23, 1477-1483.	0.9	6
258	Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 226-230.	0.6	6
259	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2016, 10, 64-68.	0.6	6
260	Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1777-1779.	1.9	5
261	Atherosclerotic Renal Artery Stenosis: Medical Therapy Alone or in Combination with Revascularization?. <i>Angiology</i> , 2009, 60, 397-402.	0.8	5
262	The DEFINE study: a bright future for CETP inhibitors?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 311-314.	1.9	5
263	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 287-288.	0.9	5
264	Therapeutic options for statin-intolerant patients. <i>Current Medical Research and Opinion</i> , 2012, 28, 345-349.	0.9	5
265	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1059-1066.	0.6	5
266	Contrast-induced acute kidney injury: beware of the risk after coronary angiography. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 73-73.	0.6	5
267	Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2018, 16, 104-106.	0.8	5
268	Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 122-125.	0.6	5
269	New-onset diabetes after transplantation. <i>Lancet, The</i> , 2005, 365, 1766.	6.3	4
270	Impact of Statins on Glucose Metabolism—A Matter of Debate. <i>American Journal of Cardiology</i> , 2011, 107, 1866.	0.7	4



#	ARTICLE	IF	CITATIONS
271	Achieving lipid targets in primary care settings. <i>Current Medical Research and Opinion</i> , 2014, 30, 1971-1974.	0.9	4
272	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	0.9	4
273	Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay. <i>Angiology</i> , 2018, 69, 745-748.	0.8	4
274	Carotid intima-media thickness as a target for organ damage and treatment target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 255-257.	1.0	4
275	Homocysteine: An Emerging Cardiovascular Risk Factor that Never Really Made it. <i>The Open Clinical Chemistry Journal</i> , 2010, 3, 19-24.	0.7	4
276	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia -A Pilot Study. <i>Current Medical Research and Opinion</i> , 2001, 17, 267-272.	0.9	3
277	Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Patients With Diabetes Mellitus and Mixed Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 101, 1679-1680.	0.7	3
278	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009, 63, 15-18.	0.8	3
279	A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone. <i>Clinical Cardiology</i> , 2009, 32, 230-230.	0.7	3
280	Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]. <i>Current Vascular Pharmacology</i> , 2010, 8, 1-4.	0.8	3
281	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. <i>Journal of Clinical Lipidology</i> , 2012, 6, 93.	0.6	3
282	Editorial The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , 2012, 1, 6-10.	0.4	3
283	Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 861-862.	1.5	3
284	Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	3
285	Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. <i>Current Medical Research and Opinion</i> , 2014, 30, 57-58.	0.9	3
286	Treating Heart Failure With Preserved Ejection Fraction. <i>Angiology</i> , 2014, 65, 328-329.	0.8	3
287	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 912.	1.2	3
288	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 471-472.	0.9	3

#	ARTICLE	IF	CITATIONS
289	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , 2015, 238, 182-184.	0.4	3
290	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1073-1073.	1.0	3
291	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G681-G682.	1.6	3
292	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. <i>Hormones</i> , 2018, 17, 83-95.	0.9	3
293	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154796.	1.5	3
294	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia - A Pilot Study. <i>Current Medical Research and Opinion</i> , 2001, 17, 267-272.	0.9	3
295	EDITORIAL - Is There a Role for Hypolipidaemic Drug Therapy in the Prevention or Treatment of Microvascular Complications of Diabetes?. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 28-32.	0.6	3
296	Effect of antihypertensive drug-associated diabetes on cardiovascular risk. <i>Hellenic Journal of Cardiology</i> , 2010, 51, 195-9.	0.4	3
297	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. <i>Clinical Lipidology</i> , 2016, 11, 2-5.	0.4	3
298	Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia. <i>Current Therapeutic Research</i> , 1994, 55, 914-924.	0.5	2
299	Additional Effects of Statins in Surgical Patients. <i>Annals of Surgery</i> , 2008, 248, 140-141.	2.1	2
300	Comment and reply on: Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 1005-1006.	1.0	2
301	Alanine Aminotransferase Is Associated With Metabolic Syndrome Independently of Insulin Resistance. <i>Circulation Journal</i> , 2011, 75, 2027.	0.7	2
302	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2141-2142.	0.9	2
303	Does Metabolic Syndrome Influence Outcome Following Percutaneous Coronary Intervention?. <i>Angiology</i> , 2011, 62, 437-439.	0.8	2
304	Response to Mildly Decreased Glomerular Filtration Rate Is Associated With Poor Coronary Heart Disease Outcome. <i>Clinical Cardiology</i> , 2012, 35, 315-315.	0.7	2
305	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , 2013, 7, 88.	0.6	2
306	Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients. <i>Current Medical Research and Opinion</i> , 2013, 29, 791-792.	0.9	2

#	ARTICLE	IF	CITATIONS
307	Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and) Tj ETQq1 1 0.784314 rgBT /Ove Design, 2014, 20, 6215-6219.	0.9	2
308	Caloric and fat intake in statin users. <i>Nature Reviews Endocrinology</i> , 2014, 10, 450-451.	4.3	2
309	Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action. <i>Indian Heart Journal</i> , 2016, 68, 596-598.	0.2	2
310	Arterial stiffness correlates with the severity of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2017, 263, e197.	0.4	2
311	Subclinical target organ damage in primary aldosteronism. <i>Journal of Hypertension</i> , 2018, 36, 701.	0.3	2
312	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 634-636.	1.0	2
313	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 469-471.	1.0	2
314	Statin use in patients with diabetes: one drug, multiple benefits. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 839-840.	0.6	2
315	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1578-1579.	1.0	2
316	NAFLD and Statins. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3052-3053.	1.1	2
317	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. <i>International Journal of Cardiology</i> , 2020, 316, 240-241.	0.8	2
318	Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia. <i>Current Vascular Pharmacology</i> , 2021, 19, 449-450.	0.8	2
319	Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 1996, 11, 196-204.	1.1	1
320	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. <i>Current Vascular Pharmacology</i> , 2007, 5, 173-174.	0.8	1
321	Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]. <i>Current Pharmaceutical Design</i> , 2010, 16, 3767-3769.	0.9	1
322	Raised liver enzymes in patients taking statins – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1075-1076.	6.3	1
323	Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management. <i>Current Vascular Pharmacology</i> , 2011, 9, 465-470.	0.8	1
324	Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]. <i>Current Vascular Pharmacology</i> , 2012, 10, 745-747.	0.8	1

#	ARTICLE	IF	CITATIONS
325	Alcohol consumption and the heart. <i>International Journal of Cardiology</i> , 2013, 168, 4319.	0.8	1
326	Prevalence and Clinical Outcome of Polyvascular Atherosclerotic Disease in Patients Undergoing Coronary Intervention. <i>Circulation Journal</i> , 2013, 77, 1348.	0.7	1
327	Cold Temperature and Cardiovascular Mortality. <i>Circulation Journal</i> , 2013, 77, 2846.	0.7	1
328	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 295-296.	0.6	1
329	Off target effects of statins shape total mortality?. <i>Journal of Drug Assessment</i> , 2016, 5, 4-5.	1.1	1
330	Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 117, 311-312.	0.7	1
331	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e6.	1.5	1
332	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , 2018, 20, 589-591.	1.0	1
333	What is the role of statins in the elderly population?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 329-331.	1.3	1
334	Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality. <i>Current Vascular Pharmacology</i> , 2018, 16, 206-208.	0.8	1
335	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. <i>Current Medical Research and Opinion</i> , 2019, 35, 1305-1306.	0.9	1
336	Multifactorial treatment of diabetic patients with cardiovascular disease to maximize results. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107904.	1.2	1
337	Ertugliflozin + metformin as a treatment option for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2105-2111.	0.9	1
338	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , 2016, 32, 1639-1640.	0.9	1
339	Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 5542-5547.	0.9	1
340	Pitfalls in the Evaluation of Uric Acid as a Risk Factor for Vascular Disease~!2009-10-29~!2009-12-23~!2010-04-08~!. <i>The Open Clinical Chemistry Journal</i> , 2010, 3, 44-50.	0.7	1
341	Letter to Editor: Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. <i>Oman Medical Journal</i> , 2012, 27, 177-177.	0.3	1
342	Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. <i>Clinical Lipidology</i> , 2018, 13, 1-3.	0.4	1

#	ARTICLE	IF	CITATIONS
343	Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic Journal of Cardiology, 2006, 47, 298-307.	0.4	1
344	Multifactorial intervention for the prevention of vascular complications of type 2 diabetes. Hellenic Journal of Cardiology, 2009, 50, 445-8.	0.4	1
345	Residual cardiac risk reduction beyond lipid lowering. Hellenic Journal of Cardiology, 2011, 52, 197-203.	0.4	1
346	Long-Term Follow-Up of a Patient with Carcinoid Disease of the Heart. American Journal of Noninvasive Cardiology, 1994, 8, 171-173.	0.1	0
347	Vascular Disease and Insulin-Like Growth Factor-1. Vascular Disease Prevention, 2007, 4, 306-313.	0.2	0
348	Unusual Manifestation of Diarrhea-Associated Haemolytic Uraemic Syndrome in an Adult. Renal Failure, 2008, 30, 331-334.	0.8	0
349	Can We Move Forward After ADVANCE?. Vascular Disease Prevention, 2008, 5, 72-74.	0.2	0
350	Fibrinogen, Hematocrit, and Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 113-114.	0.7	0
351	Comment to "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property". Digestive and Liver Disease, 2013, 45, 82-83.	0.4	0
352	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. Clinical Lipidology, 2013, 8, 509-512.	0.4	0
353	Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review. Diseases (Basel, Switzerland), 2013, 1, 51-72.	1.0	0
354	Reaching hypertriglyceridemia goals. Current Medical Research and Opinion, 2014, 30, 391-393.	0.9	0
355	Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Current Medical Research and Opinion, 2014, 30, 2425-2428.	0.9	0
356	Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention. Current Medical Research and Opinion, 2014, 30, 55-55.	0.9	0
357	Are antibodies against PCSK9 the statins of the 21st century?. Clinical Lipidology, 2014, 9, 141-144.	0.4	0
358	Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A. Current Vascular Pharmacology, 2015, 13, 696-698.	0.8	0
359	Cardiovascular Risk in Middle East Populations. Angiology, 2015, 66, 801-802.	0.8	0
360	Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Current Vascular Pharmacology, 2016, 14, 271-274.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Statins, renal function and homocysteine. <i>Pharmacological Reports</i> , 2016, 68, 1093.	1.5	0
362	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. <i>Curr Med Res Opin</i> 2017;33:797-801. <i>Current Medical Research and Opinion</i> , 2017, 33, 2261-2262.	0.9	0
363	Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. <i>J Clin Lipidol</i> . 2016;10(5):1091-1097. <i>Journal of Clinical Lipidology</i> . 2017, 11, 306-307.	0.6	0
364	Meet Our Section Editor. <i>Current Vascular Pharmacology</i> , 2017, 16, .	0.8	0
365	Statins and substantially increased <sc>ALT</sc> values at baseline. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12444.	1.1	0
366	Children With Familial Hypercholesterolemia: Cardiometabolic Profile Data From The Hellas-Fh Registry. <i>Atherosclerosis</i> , 2019, 287, e210.	0.4	0
367	Effect Of High And Low Dose Of Rosuvastatin On Fatty Liver Disease And 24-Hour Arterial Stiffness In Patients With Non-Alcoholic Fatty Liver Disease. <i>Atherosclerosis</i> , 2019, 287, e203.	0.4	0
368	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 3597-3598.	0.9	0
369	Coronary angiography and acute kidney injury: The dawn for novel markers. <i>International Journal of Cardiology</i> , 2020, 304, 175-176.	0.8	0
370	Coronary angiography and acute kidney injury: The dawn for novel markers. <i>International Journal of Cardiology</i> , 2020, 300, 119-120.	0.8	0
371	Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e39-e40.	0.4	0
372	Effect of high and low dose of rosuvastatin on fatty liver disease and adipokines in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2020, 315, e98-e99.	0.4	0
373	Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e210-e211.	0.4	0
374	Latest European guidelines for dyslipidemias in the setting of familial hypercholesterolemia: Data from the hellas-fh registry. <i>Atherosclerosis</i> , 2020, 315, e41.	0.4	0
375	Coexistence of cardiovascular risk factors in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e211.	0.4	0
376	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: A systematic review and meta-analysis of randomized-controlled trials. <i>Atherosclerosis</i> , 2020, 315, e41.	0.4	0
377	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. <i>Angiology</i> , 2022, 73, 000331972110055.	0.8	0
378	More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Hormones</i> , 2016, 15, 5-7.	0.9	0

#	ARTICLE	IF	CITATIONS
379	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. Open Hypertension Journal, 2017, 9, 1-5.	0.8	0
380	Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments. Current Vascular Pharmacology, 2020, 19, 673-674.	0.8	0
381	Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy. Current Vascular Pharmacology, 2014, , .	0.8	0
382	Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy. Current Vascular Pharmacology, 2015, 13, 223-5.	0.8	0
383	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101842.	0.7	0